InVitria optimizes hybridoma cell culture with Zap-Hybridoma
5 March 2010
InVitria’s launch of Zap-Hybridoma provides a powerful
solution for hybridoma cell culture. Zap-Hybridoma was created to
improve monoclonal antibody productivity and deliver easier purification
of the target product.
Zap-Hybridoma was developed by InVitria’s Cell Culture
Development team as an answer to many of the challenges facing
scientists working with hybridoma cell culture.
“Not only can Zap-Hybridoma increase productivity, it delivers
consistent results and allows hybridoma cells to more quickly adapt
away from FBS (fetal bovine serum),” said Dr. Steve Pettit,
InVitria’s Director of Cell Culture Development.
“We tested Zap-Hybridoma in six of the leading commercial
hybridoma media on the market today and observed faster cell growth,
a 50% average increase in maximum cell density and increased
monoclonal antibody yield when compared to the recommended use of
“Zap-Hybridoma is an innovation InVitria is proud to bring to its
customers so they can achieve better performance more consistently,”
said Scott Deeter, InVitria President and CEO. “We developed
Zap-Hybridoma to give users an IgG free alternative to FBS without